Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-12-11
2000-01-04
Woodward, Michael P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530316, A61K 3800
Patent
active
060110155
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to the use of angiotensin II, or an analogue thereof, for promoting fertilization of mammalian eggs, especially human eggs. In particular, it relates to the use of angiotensin II to improve sperm motility. The invention also relates to a method of promoting in vitro fertilization.
Angiotensin II is an octapeptide, usually regarded as being produced in the blood, firstly by the action of renin, an enzyme secreted by the kidney, on angiotensinogen, resulting in the formation of the decapeptide precursor, angiotensin I, and secondly the action of a dipeptidase "angiotensin converting enzyme"; this enzyme acts on angiotensin I to form angiotensin II. Angiotensin II, in turn, undergoes hydrolysis by an aminopeptidase to yield the heptapeptide angiotensin III (angiotensin 1-7).
The hormone angiotensin II (Ang II) forms part of the renin--angiotensin system which helps to control electrolyte balance and blood pressure within the body. There are several tissues within the body upon which Ang II acts, they include the adrenal gland, uterus, liver, brain and kidney.
Amongst the several established functions of angiotensin II, it is known to be involved in vasoconstriction, which leads to hypertension. Most treatments for high blood pressure will include blockage of angiotensin function in one way or another. Ang II also stimulates the secretion of aldosterone by the adrenal cortex. Aldosterone is a potent hormone which acts primarily on the kidney to promote sodium retention and thus inter alia, heightens the hypertensive effects of angiotensin acting directly on the vasculature.
Ang II is known to act on various sites in the brain, and one of its actions in animals is the regulation of thirst and drinking.
Angiotensin also has trophic effects on the vasculature, promoting growth of the muscles in the arterial wall. It is also thought to be angiogenic, i.e. it causes vascularisation of newly developing tissue.
Most of the established effects of Ang II have been found to occur via the AT.sub.1 subtype of the Ang II receptor, which is a seven transmembrane domain receptor. This receptor has been cloned and sequenced from a variety of tissues, and has been found to be a 359 amino acid polypeptide with a predicted molecular weight of around 40 kD (Bernstein and Alexander, (1992), Endocr. Rev. 13, 381-386). Studies using photo-affinity labeling and cross linking agents have suggested molecular weights for mature receptor of approximately 65 kD and 116 kD, respectively, which may reflect glycosylation of asparagine residues within the extra-cellular domain.
From the recent development of a hybridoma cell line. see Baker, S., et al, J. Mol. Endocr. 11, 241-245, (1993), it has been found possible to produce monoclonal antibodies to the AT.sub.1 subtype of the Ang II receptor. In consequence, such receptors have been found to exist both on maturing rat and human sperm tails, and on free swimming sperm obtained by vaginal lavage from mated rats, and in human ejaculated sperm.
SUMMARY OF THE INVENTION
It has now been found that angiotensin II, or an analogue thereof, increases both the percentage of motile sperm and their linear velocity.
This newly discovered property of angiotensin II enable Ang II to be used to promote fertilization, since the capacity of sperm to fertilize ova is closely related to their motility.
According to one aspect of the invention there is provided the use of angiotensin II or a salt or analogue thereof to promote fertilization of mammalian eggs. Such fertilization may take place in vitro.
According to a second aspect of the invention there is provided the use of angiotensin II, or a salt or analogue thereof to increase sperm motility.
According to another aspect of the invention there is provided the use of angiotensin II, or a salt or analogue thereof, for the manufacture of a medicament for use in promoting fertilization, in particular in vitro fertilization.
According to yet another aspect of the invention there is provided a method o
REFERENCES:
patent: 5338744 (1994-08-01), Dudley et al.
C. De Geyter, et al.; Int. Journal of Andrology, 15, pp. 485-497 (1992).
H. Holland-Moritz and W. Krause; Int. Journal of Andrology, 15, pp. 473-485 (1992).
G.J. Vulcano, et al.; Mathematical Biosciences, 149, pp. 77-93 (1998).
S.T. Mortimer and D. Mortimer, Journal of Andrology, 11, pp. 195-203 (1990).
S.T. Mortimer, Human Reproduction Update, 3 (5), pp. 403-439 (1997).
Koyama Norihiro, Kyorin Igakkai Zasshi, vol. 24, No. 4, pp. 517-528, 1993.
Sharpe et al., J. Physiol. (London), 239(3), pp. 595-622, 1974.
Koyama Norihiro, Kyorin Igakkai Zasshi, vol. 24, No. 4, pp. 517-528 (abstract), 1993.
Mizutani et al., Andrologia 17(2): 150-156, 1985.
Kaneko et al., J. Pharm. Dyn. 7, pp. 87-93, 1984.
Delacroix-Muirheid C.
Queen Mary & Westfield College
Woodward Michael P.
LandOfFree
Angiotensin II for improving fertilization does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiotensin II for improving fertilization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin II for improving fertilization will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1072729